喵咪社区

A 喵咪社区 physician-scientist discusses the future possibilities of turning a tumor into its own vaccine. 

At 喵咪社区 Norris Comprehensive Cancer Center, part of 喵咪社区, physician-scientists are rethinking how the immune system can be mobilized against cancer. Rather than targeting a single tumor antigen 鈥� a strategy that has historically limited the effectiveness of cancer vaccines 鈥� Fumito Ito, MD, PhD, a surgical oncologist with 喵咪社区 Norris Comprehensive Cancer Center, is advancing a fundamentally different approach: activating the body鈥檚 immune system directly within the tumor microenvironment to recognize and attack a broad spectrum of cancer signals. 

Ito鈥檚 work centers on in situ immunomodulation (ISIM), an approach sometimes referred to as 鈥渋n situ vaccination,鈥� though it differs significantly from traditional vaccine mechanisms.  

鈥淲hen you hear 鈥榗ancer vaccine,鈥� you typically think about targeting one or two specific antigens,鈥� Ito says. 鈥淏ut tumors are heterogeneous. They express many known and unknown antigens simultaneously. With ISIM, instead of selecting targets in advance, we allow the immune system to identify them.鈥� 

Turning the Tumor into Its Own Vaccine 

The protocol Ito developed is a multistep, combination strategy designed to orchestrate a coordinated immune response. It begins with the intratumoral injection of CDX-301, a cytokine that recruits conventional type 1 dendritic cells (cDC1s) 鈥� key orchestrators of antitumor immunity 鈥� into the tumor. 

鈥淭hese dendritic cells are like the commander-in-chief of the immune system,鈥� Ito says. 鈥淭hey are essential for initiating a strong T-cell response.鈥� 

Next, localized radiation therapy is applied to induce tumor cell death, releasing a wide array of tumor antigens. The recruited dendritic cells then process and present these antigens to T cells. Finally, immune-stimulating agents 鈥� including CDX-1140 and poly-ICLC 鈥� are administered to activate the dendritic cells and amplify T-cell priming. 

The result is a dynamic, multi-antigen immune response that extends beyond the treated lesion. In preclinical models, this approach demonstrated activity not only in injected tumors but also in distant metastatic sites 鈥� suggesting the potential for systemic disease control. 

From the Clinic to the Lab and Back Again 

In , Ito and his team observed encouraging responses from this protocol in a subset of patients. 鈥淲e鈥檝e seen tumor shrinkage and, in some cases, complete disappearance of tumors,鈥� he says. 鈥淧ost-treatment biopsies have occasionally shown no residual cancer.鈥� 

But in the initial cohort, not all patients responded as Ito expected.  

鈥淎fter treating the first several patients, we identified a potential limitation involving interleukin-6 (IL-6),鈥� he says. 鈥淲e hypothesized that IL-6 signaling might be restricting the full immune response.鈥� 

As a physician-scientist at an academic medical system, he was able to quickly move back to the lab to figure out the problem. His team tested this hypothesis in preclinical animal models and confirmed that blocking IL-6 significantly enhanced treatment efficacy. This insight led to a protocol modification in a subsequent patient cohort, incorporating an IL-6 receptor inhibitor (tocilizumab) alongside anti-PD-1 therapy to remove the suppression in the full immune response. 

鈥淲ith these additions, we began to see improved responses,鈥� Ito says. 鈥淭his bidirectional approach 鈥� moving from patients to the lab and back again 鈥� allowed us to refine the therapy in real time.鈥� 

The Future of Cancer Immunotherapies 

This study demonstrated that the treatment is safe and well tolerated, with limited systemic toxicity. Because the approach relies on direct tumor injection, it is broadly applicable across tumor types that are accessible for intratumoral therapy, Ito says. 

While the study was not powered to determine efficacy by cancer subtype, early signals were observed in patients with breast cancer and squamous cell carcinoma. These indications may serve as a focus for future trials, and Ito is optimistic about the potential of this strategy. 

鈥淲e鈥檙e seeing not only clinical responses but also clear evidence of immune activation both within tumors and in the peripheral blood,鈥� he says. 鈥淭hat gives us confidence as we move into the next phase of development.鈥� 

He anticipates that full study results will be published in 2027. 

鈥淭his type of research underscores the importance of clinical trial funding, awareness and collaboration,鈥� Ito says. 鈥淧atients who have progressed on standard therapies may still have meaningful options through investigational protocols like these.鈥�

Topics

Mollie Barnes

Mollie Barnes is a digital writer and editor with 喵咪社区.

Share